Inventory Turnover measures how fast the company turns over its inventory within a year.
Rigel Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.40.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Rigel Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.20.
Rigel Pharmaceuticals (FRA:RI2) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Rigel Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Rigel Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Rigel Pharmaceuticals Days Inventory Related Terms
Rigel Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Rigel Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RI2 vs CADL, IMMX, AURA: Days Inventory Comparison
For the Biotechnology subindustry, Rigel Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (FRA:RI2) has a Days Inventory of 227.90 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Rigel Pharmaceuticals and its competitors. This is 57% below median its historical median of 531.47. Over the past decade, Rigel Pharmaceuticals' Days Inventory has ranged from 112.79 to 1,641.77. According to the industry distribution chart, Rigel Pharmaceuticals ranks #329 out of 638 companies in the Biotechnology industry, placing it in the top 51.6%.
Is Rigel Pharmaceuticals' Days Inventory too high?
Rigel Pharmaceuticals' current Days Inventory of 227.90 is 57% below median its 10-year median of 531.47. Over the past 10 years, this metric has ranged from a low of 112.79 to a high of 1,641.77. The Biotechnology industry median Days Inventory is 183.88. Rigel Pharmaceuticals' value of 227.90 is 23.9% above this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #329 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Days Inventory compare to CADL and IMMX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #329 out of 638 companies for Days Inventory. This places Rigel Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 183.88. Rigel Pharmaceuticals' value of 227.90 is 23.9% above this benchmark. Historically, Rigel Pharmaceuticals' own Days Inventory has ranged from 112.79 to 1,641.77 over the past decade. While the company's 10-year median is 531.47 vs. the industry median of 183.88, Rigel Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current Days Inventory of 227.90 is 23.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Rigel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current Days Inventory is 227.90, which is 57% below median its own 10-year median of 531.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Days Inventory of 227.90. The stock's GF Value™ is €24.33, compared to a current price of €33.59 — trading 38.1% above its estimated fair value. The current Days Inventory is 227.90, which is 57% below median its 10-year median of 531.47 and 23.9% above the Biotechnology industry median of 183.88. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Days Inventory is 227.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €33.59 is trading 38.1% above its estimated GF Value™ of €24.33.
Key valuation signals for FRA:RI2:
Days Inventory: 227.90 (57% below median its 10-year median of 531.47)
GF Value™: €24.33 vs. price of €33.59 (38.1% above fair value)
Industry Position: 23.9% above the Biotechnology median (#329 of 638)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score
Get the complete analysis for FRA:RI2
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
